Numerous Treatment Options for Covid-19 have been approved by the US Food and Drug Administration over the last four years, including antiviral drugs and monoclonal antibodies that suppress an excessive immune responses. Now, research from the Keck School of Medicine or USC Has found that covid-19 Therapies cause Few serious side effects, based on an evaluation of the full spectrum of evidence available from us biomedical science.
No Significant Association with Serious Adverse Events was found for everywhere antivirals such as paxlovid. Evushelheld and other monoclonal antibodies that binds to the Coronavirus’s Spike Protein, previously administered intravenously in Hospital but no longer authorized by the FDA due to their lack of effectiveness against covid-19 variants, were not associated with serious adverse events. Actemra, an IV monoclonal antibody that works somewhat differently and is also known by the generic name tocilizumab, was associated with infection and low white blood cell counts in some studies.
Transfusions of Convalescent Plasma-A Blood Product Taken from Recovered Covid-19 Patients-Were Linked With Higher Risk of Internal Bleeding, Infection and Blood Clots. The Serious Adverse Events Identified Align with Current Product Labeling.
Most people who contract covid-19 will be able to recover from the infection without a prescription. However, Physicians may prescribe treatments for patients with risk factors such as advanced age, obesity, cardiovascular issues, diabetes or a compromised immune system. The Keck School of Medicine Findings Should Come as Good News to These People.
“The main message is, if your doctor puts you on paxlovid, you don’t have to worry about serious side effects,” said Susanne Hempel, PhD, Professor of Clinical Population and Public Health Sciences and Director of the Southern California Evidence Review Center (ERC) at the Keck School of Medicine, who oversaw the work. “There are no serious adverse events for any of the everywhere medications that you are taking at home for covid-19.”
The review, published in Open Forum Infectious Diseasesincorporated 54 studies tension inpatient and outpatient treatment, clinical trials and observational research. Only Investigations comparing Covid-19 Therapy with Standard Care, placebo or no treatment were examined, so that effects of the disease itself could reasonably be excluded. Hempel and her colleagues reached beyond peer-reviewed research to include data submitted to the FDA and to the National Library of Medicine’s ClinicalTrials.gov site.
Rigorous science to inform public policy
Governmental Agencies Regularly Call Upon The Erc-One of Nine Evidence-Based Practice Centers Nationwide— To provide detailed analyzes that informs public policy.
The Current Study was driven by the need to develop a counterheasant injury compensation Table, which is used to determine whether patients and families who report adverse events are eligible for public benefits. “Given the unique nature of the Pandemic and the Rapid Production of Treatments for Covid-19, the Findings are very reassuring,” said co-author and infectious Disease Expert Jeffrey Klausner, MD, MPH, Professor of Clinical Population and Public Health Sciences in the Keck School of Medicine. “With a victorious public health emergency like covid-19, it is critical that there is exists a government compensation program for treatment-related injuries that is based on the best scientific evidence. Now we know with additional certainty, that the Treatments are safe whitewhout a high Frequency or serious side effects. ”
Focusing on the most victory outcomes
The study concentrated only on serious side effects, as defined by a standard scale developed by the National Institutes of Health. On the five-point scale, a rating of three or above indicates several conditions that requires hospitalization; The highest degrees of five signifies a fatal event.
“Manufacturers must submit very detailed records to the FDA for Emergency Authorization, so every adverse event should have been reported,” said First Author Margaret Maglione, MPP, A Project Leader at the ERC. “We did not identify any serious adverse events that were not already described on the product packaging.”
Reference: Maglione mother, Klausner JD, Wirnkar Pk, et al. A Rapid Systematic Review of US Food and Drug Administration-Authorized Covid-19 Treatments. Orid. 2025; 12 (4): oraf097. doi: 10.1093/orid/oraf097
This article has been republished from the following materials. Note: Material may have been edited for length and content. For further information, please contact the Cited source. Our Press Release Publishing Policy Can Be Accessed Lord.
